Underwhelmed by Big Pharma’s ‘Largesse’ « The Washington Independent
Jul 31, 202022.5K Shares1.2M Views
Sens. Byron Dorgan (D-N.D.) and Olympia Snowe (R-Maine) just shot out a statement reacting to the recent dealcut between the White House and the pharmaceutical industry to trim prescription drug costs for millions of Medicare patients. Here’s a hint: They’re not terribly impressed.
“Even with PhRMA’s offer to help seniors,” says Dorgan, “American consumers will continue to pay the highest price for prescription drugs in the world.”
“The fact is,” adds Snowe, “that while the announced savings are substantial, they amount to less than 4 percent of our nation’s annual prescription drug spending, and when you consider that other developed nations pay 35-55% less for their medications, it certainly doesn’t close the gap much.”
For years, the two lawmakers have pushed legislation— anathema to drug companies — allowing U.S. pharmacists to import Food and Drug Administration-approved drugs from some countries abroad, where costs are much lower, and pass the savings on to domestic consumers. (Current law limits the importation of prescription drugs exported by the United States).
Obama, as senator, was a sponsor of the same bill. By agreeing to take an estimated $80 billion haircut under Medicare’s drug benefit, however, the drug makers are surely hoping to stave off further cuts, like the Dorgan-Snowe bill certainly represent.
Camilo Wood
Reviewer
Camilo Wood has over two decades of experience as a writer and journalist, specializing in finance and economics. With a degree in Economics and a background in financial research and analysis, Camilo brings a wealth of knowledge and expertise to his writing.
Throughout his career, Camilo has contributed to numerous publications, covering a wide range of topics such as global economic trends, investment strategies, and market analysis. His articles are recognized for their insightful analysis and clear explanations, making complex financial concepts accessible to readers.
Camilo's experience includes working in roles related to financial reporting, analysis, and commentary, allowing him to provide readers with accurate and trustworthy information. His dedication to journalistic integrity and commitment to delivering high-quality content make him a trusted voice in the fields of finance and journalism.
Latest Articles
Popular Articles